摘要
目的探讨黄连素对结直肠腺瘤(colorectal adenoma,CRA)内镜下切除后复发的预防作用。方法126例经内镜下黏膜切除术(endoscopic mucosal resection,EMR)切除的CRA患者为研究对象,按照随机双盲原则分为干预组(n=42)、安慰剂组(n=42)及对照组(n=42)。干预组给予黄连素片0.1 g,口服,3次/d;安慰剂组给予相同剂量的安慰剂口服,对照组不给予任何药物干预。对比分析3组患者内镜下切除后6、12、18个月内CRA复发率。结果CRA内镜下切除后12个月及18个月内CRA复发率干预组(10.0%、12.5%)均较安慰剂组(30.0%、35.0%)及对照组(31.7%、36.6%)显著降低(P<0.05),安慰剂组与对照组相比,差异无统计学意义(P>0.05)。随访18个月,干预组药品不良反应发生率为25.0%,但不良反应均轻微,不影响继续服药。结论黄连素对CRA内镜下切除后的复发具有一定的预防价值,且可行性及耐受性较好,黄连素有望成为CRA复发的化学预防药物之一。
Objective To explore the preventive effects of Berberine in the recurrence of colorectal adenoma(CRA)after endoscopic resection.Methods 126 patients with CRA and excised by endoscopic mucosal resection(EMR)were divided into intervention group(n=42),placebo group(n=42),and blank control group(n=42)randomly and double-blindly.The patients in intervention group and placebo group were separately arranged to intake 0.1 g Berberine,placebo of Berberine,but the patients in control group did not take any medicine.The recurrence rates of CRA after 6,12,18 months of intervention were compared among the 3 groups.Results After 12 or 18 months,the recurrence rates of CRA in intervention group(10.0%,12.5%)were obviously decreased than placebo group(30.0%,35.0%)or control group(31.7%,36.6%)(P<0.05),and there was no significant difference between placebo group and control group(P>0.05).The total incidence rate of the adverse reactions in intervention group was 25.0%during 18 months,but all the adverse reactions were mild and did not affect continuing drug intakeing.Conclusion Berberine can prevent the recurrence of CRA after endoscopic resection,and it can be used as an adaptable chemopreventive agent to prevent the recurrence of CRA.
作者
王伟强
李晓
陈玉华
刘世萍
唐光明
WANG Weiqiang;LI Xiao;CHEN Yuhua;LIU Shiping;TANG Guangming(Department of Gastroenterology,the Seventh People’s Hospital in Chongqing,Chongqing 400054,China)
出处
《胃肠病学和肝病学杂志》
CAS
2020年第1期46-49,共4页
Chinese Journal of Gastroenterology and Hepatology
基金
重庆市卫生计生委科研项目(2017MSXM162)
关键词
结直肠腺瘤
黄连素
复发
预防
Colorectal adenoma
Berberine
Recurrence
Prevention